open access

Vol 9, No 3 (2005)
Prace oryginalne
Published online: 2005-05-11
Get Citation

Effect of one-month therapy of amlodipine on plasma endothelin-1 concentration in hypertensive patients

Hanna Kara-Perz, Teresa Kosicka, Jerzy Głuszek, Lech Torliński
Nadciśnienie tętnicze 2005;9(3):202-207.

open access

Vol 9, No 3 (2005)
Prace oryginalne
Published online: 2005-05-11

Abstract

Background Contemporary treatment of hypertension comprises also drugs affecting endothelium, increasing synthesis of vasorelaxating agents and decreasing synthesis of vasoconstrictory substances. One of these substances is endothelin-1 (ET-1). Literature shows us variability of calcium antagonists (A-Ca2+) influence on ET-1 concentration. Synthesis of ET-1 depends on many physical and chemical factors which may be influenced by A-Ca2+ administration. Particularly important are adrenergic system and RAA system. The aim of this study was to assess the influence of amlodipine on plasma ET-1 and aldosterone concentrations in patients with essential hypertension.
Material and methods Investigation involved 11 patients with essential hypertension (SBP — Me 152,5 ± 6,8 mm Hg, DBP — Me 95,0 ± 3,44 mm Hg) without any additional diseases that might have influenced plasma ET-1 concentration.
In each patient were assessed: a) SBP and DBP; b) plasma ET-1 concentration (radioimmunoassay); c) plasma aldosterone concentration (radioimmunoassay); before (I measurement) and after 30 days (II measurement) of amlodipine administration (5 mg/d).
Results One-month therapy of 5 mg of amlodipine/day causes: 1. significant decrease of SBP (Me ± S: I meas.: 152,5 ± 6,8 mm Hg vs. II meas.: 130,0 ± 8,3 mm Hg, p < 0.007); 2. significant decrease of DPP (Me ± S: I meas.: 95,0 ± 3,44 mm Hg vs. II meas.: 80,8 ± 5,74 mm Hg, p < 0.0003); 3. non-significant decrease of ET-1 concentration (Me ± S: I meas.: 110,5 ± 34,9 pg/ml vs. II meas.: 99,7 ± 21,2 pg/ml, p = 0.53); 4. non significant changes of aldosterone concentration (Me ± S: I meas.: 169,8 ± 114,1 pg/ml vs. II meas.: 162,1 ± 72,7 pg/ml, p = 0.18).
Conclusion In our investigation the administration of amlodipine 5 mg/d. not influencing RAA system (no changes in aldosterone concentration) leads to non-significant decrease of ET-1 concentration. However, small number of patients and clear trend to decrease ET-1 concentration seems to require continuation of investigation.

Abstract

Background Contemporary treatment of hypertension comprises also drugs affecting endothelium, increasing synthesis of vasorelaxating agents and decreasing synthesis of vasoconstrictory substances. One of these substances is endothelin-1 (ET-1). Literature shows us variability of calcium antagonists (A-Ca2+) influence on ET-1 concentration. Synthesis of ET-1 depends on many physical and chemical factors which may be influenced by A-Ca2+ administration. Particularly important are adrenergic system and RAA system. The aim of this study was to assess the influence of amlodipine on plasma ET-1 and aldosterone concentrations in patients with essential hypertension.
Material and methods Investigation involved 11 patients with essential hypertension (SBP — Me 152,5 ± 6,8 mm Hg, DBP — Me 95,0 ± 3,44 mm Hg) without any additional diseases that might have influenced plasma ET-1 concentration.
In each patient were assessed: a) SBP and DBP; b) plasma ET-1 concentration (radioimmunoassay); c) plasma aldosterone concentration (radioimmunoassay); before (I measurement) and after 30 days (II measurement) of amlodipine administration (5 mg/d).
Results One-month therapy of 5 mg of amlodipine/day causes: 1. significant decrease of SBP (Me ± S: I meas.: 152,5 ± 6,8 mm Hg vs. II meas.: 130,0 ± 8,3 mm Hg, p < 0.007); 2. significant decrease of DPP (Me ± S: I meas.: 95,0 ± 3,44 mm Hg vs. II meas.: 80,8 ± 5,74 mm Hg, p < 0.0003); 3. non-significant decrease of ET-1 concentration (Me ± S: I meas.: 110,5 ± 34,9 pg/ml vs. II meas.: 99,7 ± 21,2 pg/ml, p = 0.53); 4. non significant changes of aldosterone concentration (Me ± S: I meas.: 169,8 ± 114,1 pg/ml vs. II meas.: 162,1 ± 72,7 pg/ml, p = 0.18).
Conclusion In our investigation the administration of amlodipine 5 mg/d. not influencing RAA system (no changes in aldosterone concentration) leads to non-significant decrease of ET-1 concentration. However, small number of patients and clear trend to decrease ET-1 concentration seems to require continuation of investigation.
Get Citation

Keywords

endothelin-1; amlodipine; essential hypertension

About this article
Title

Effect of one-month therapy of amlodipine on plasma endothelin-1 concentration in hypertensive patients

Journal

Arterial Hypertension

Issue

Vol 9, No 3 (2005)

Pages

202-207

Published online

2005-05-11

Bibliographic record

Nadciśnienie tętnicze 2005;9(3):202-207.

Keywords

endothelin-1
amlodipine
essential hypertension

Authors

Hanna Kara-Perz
Teresa Kosicka
Jerzy Głuszek
Lech Torliński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl